Search hospitals > California > Long Beach

Pacific Shores Medical Group

Claim this profile
Long Beach, California 90813
Global Leader in Breast Cancer
Global Leader in Pancreatic Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Prostate Cancer
82 reported clinical trials
3 medical researchers
Photo of Pacific Shores Medical Group in Long BeachPhoto of Pacific Shores Medical Group in Long BeachPhoto of Pacific Shores Medical Group in Long Beach

Summary

Pacific Shores Medical Group is a medical facility located in Long Beach, California. This center is recognized for care of Breast Cancer, Pancreatic Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Prostate Cancer and other specialties. Pacific Shores Medical Group is involved with conducting 82 clinical trials across 98 conditions. There are 3 research doctors associated with this hospital, such as Danny Nguyen, MD, Nishan Tchekmedyian, M.D., and Mohammad Barakat.

Area of expertise

1Breast Cancer
Global Leader
Pacific Shores Medical Group has run 19 trials for Breast Cancer. Some of their research focus areas include:
Stage III
Stage IV
NRG1 positive
2Pancreatic Cancer
Global Leader
Pacific Shores Medical Group has run 16 trials for Pancreatic Cancer. Some of their research focus areas include:
Stage IV
Stage III
NRG1 positive

Top PIs

Clinical Trials running at Pacific Shores Medical Group

Lung Cancer
Cancer
Pancreatic Cancer
Solid Tumors
Liver Failure
Non-Small Cell Lung Cancer
Neuroendocrine Carcinoma
Pulmonary Disease
Acute Viral Respiratory Infection
Thyroid Cancer
Image of trial facility.

U3-1402

for Non-Small Cell Lung Cancer

This trial is testing HER3-DXd, a new drug for advanced lung cancer patients who haven't responded to other treatments. The drug targets a protein on cancer cells and delivers a toxic substance to destroy them.
Recruiting1 award Phase 118 criteria
Image of trial facility.

Repotrectinib

for Solid Tumors

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
Recruiting1 award Phase 1 & 27 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Pacific Shores Medical Group?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security